Vaishali Pharma share price, P/E, ROE & financials

As of 6 Nov 2026, Vaishali Pharma trades at ₹6.76, 32% below its 52-week high. Sales grew 18% a year over 3 years while net profit fell 15%; its ROCE of 9.8% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.27× equity. It is a small-cap company with a market cap of ₹88 Cr, ranked 123rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 32% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Mar 2025.How we calculate this

past year

Open: ₹6.98
Day high: ₹6.98
Day low: ₹6.62
Prev. close: ₹6.81
Volume: 37.1K

Health check

2 fair · 3 to check

ReturnsBehind
−31.9% over a year, better than 0 of 7 peers.
Price tagn/a
P/E isn’t reported.
GrowthSteady
Sales +18.0%, profit −15.2% a year over 3 years.
ProfitabilityWeak
ROCE 9.8% vs peer median 17.9%.
Balance sheetFair
Debt 0.27× equity, interest covered 3.7×, Piotroski 4 of 9.
Red flags3 to check
Return on equity is low at 6.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹88 Cr, #123 of 154 in its industry by size.

Defensive

Beta 0.46 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Mar 2025: sales ₹108 Cr · profit ₹4 Cr

Market cap: ₹88 Cr; Small cap
P/E: n/a; Industry 28.7
Price to book: 1.28; Peers 4.99
Dividend yield: 0.00%
ROE: 6.0%; Peers 14.7%
ROCE: 9.8%; Peers 17.9%
Debt to equity: 0.27; Debt ₹19 Cr
EPS (TTM): ₹0.00; Face value ₹2
OPM (TTM): 5.9%; Net margin 4.1%
Sales growth: −3.6%; Latest quarter vs a year ago
Profit growth: +18.5%; Latest quarter vs a year ago
Price to sales: 0.82; EV/EBITDA 27.1

Risks to check

Return on equity is low at 6.0%.
Quarterly sales down 3.6% on a year ago.
32% below its 52-week high.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal,…

Headquarters: Mumbai
Employees: 30
Sector: Healthcare
ISIN: INE972X01022
Website: vaishalipharma.com

Price range

52 weeks

₹4.75₹9.90

Today

₹6.62₹6.98

Avg volume (3M): 1.5 L
1-year return: minus 31.9%
From 52-week high: minus 31.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
VAISHALIVaishali Pharma	6.76	minus 0.73%	88	–	1.28	9.8%	6.0%	5.9%	18.0%	−15.2%	0.00%	minus 31.9%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore · latest reported Mar 25

SalesSelect a row below to chart it

₹ Cr	Mar 25
	31.1
	30.8
	0.3
	0.8%
	0.7
	0.9
	0.1
	−5.5
	−5.6
	23.4%
	−4.3

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +18.0%
Profit CAGR 3Y: −15.2%
ROE: 6.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
63.8	81.8	97.9	105
–	+28.1%	+19.7%	+7.0%
54.3	78.1	94.1	98.5
9.5	3.7	3.8	6.2
14.8%	4.5%	3.9%	6.0%
2.1	5.1	5.5	3.8
2.3	2.3	2.1	2
0.5	0.5	0.5	0.6
–	−5.1	−5.5	−2.1
8.8	0.9	1.2	5.4
25.4%	22.4%	33.3%	25.2%
6.6	0.7	0.8	4
–	minus 89.1%	+13.7%	+393.2%
0.59	0.07	–	–

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
10.5	10.7	26.1	26.1
30	32.1	38.8	43
14.7	13.5	12.3	18.9
23.6	23.6	32.6	35.4
78.9	80	110	123
1.8	1.5	1.2	1.2
1.6	1.8	1.8	1.8
0.5	1.5	1.7	1.1
74.9	75.3	105	119
78.9	80	110	123

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1.1	0.8	−18	0.4
0.3	1.2	−0.2	−5.5
−1.7	−1.4	18.5	4.6
−0.4	0.6	0.3	−0.4
−0.3	−0.1	−0.3	−0.5
0.8	0.7	−18.3	−0

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you